Thursday, April 14, 2011
Health Equity Symposium
* Dramatic shifts in the size of global, ethnic and regional populations are expected during the next 50 years
* Symposium will explore the biological foundations of health disparity and necessary steps to refocus pharmaceutical research to address these inequities
* Topics to include biases in research-design and portfolios, tissue banks, stem cell supplies, clinical studies and regulation
What: The Novartis Institutes for BioMedical Research (NIBR) is holding its inaugural Health Equity Symposium May 3-4, which will gather scientists, clinicians and policymakers to discuss what industry, academia and government can do to help shape the way biomedical research is conducted to better serve the unique needs of each group and ensure a more equitable delivery of health care.
Who: Leading researchers and policymakers, including Dr. Julio Frenk, Dean, Harvard School of Public Health; Former Minister of Health, Mexico.
When: Tuesday, May 3 and Wednesday, May 4, 8:00 a.m. to 5:00 p.m.
Where: Visit live webcast at: www.healthequitysymposium.com
Opportunities: Hear experts from Zimbabwe’s African Institute of Biomedical Science and Technology and the U.S. National Cancer Institute, as well as faculty from Morehouse, Harvard, Duke, Michigan and Rockefeller universities.
The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis. NIBR’s global research network is comprised of more than 6,000 scientists, physicians and business professionals working together across nine locations to discover innovative medicines to treat diseases with high unmet medical need.
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group’s continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100.000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.